gene fusion expands the genetic spectrum implicated in the pathogenesis of congenital spindle cell sarcomas, with yet another example of kinase oncogenic activation through chromosomal translocation. The discovery of this new fusion is significant since the resulting MET activation can potentially be inhibited by targeted therapy, as MET inhibitors are presently available in clinical trials.
| I N T R O D U C T I O N
The diagnosis of congenital and infantile sarcomas is frequently challenging due to their rarity and overlapping morphologic features. They typically share a primitive spindle cell phenotype, arranged in intersecting fascicles, with often a nonspecific immunoprofile. Molecular genetics can be of critical importance in confirming the diagnosis and excluding other look-alike benign cellular spindle cell proliferations. For example, the presence of ETV6-NTRK3 fusion represents the gold-standard for diagnosis of congenital/infantile fibrosarcoma, 1 while the VGLL2-related fusions are often associated with congenital spindle cell rhabdomyosarcoma. 2 Tumors lacking these pathognomonic fusions are frequently grouped by default in a wastebasket category of unclassified/undifferentiated spindle cell sarcomas. The use of the latter terminology may imply a high grade malignancy and therefore is often approached with multimodality therapies, including chemo-radiation. In contrast, most fusionpositive infantile spindle cell sarcomas are associated with a favorable outcome, in which a surgically removed lesion might not require adjuvant therapy, such as chemo or radiation therapy. Furthermore, the lack of a certain diagnostic fusion gene might instead favor an alternative benign diagnosis, such as cellular/atypical infantile myofibroblastic tumors, with features of myofibroblastoma or myofibroma. 3, 4 Another example is the identification of NTRK1-related fusions in a group of locally aggressive, S100 protein-positive lipofibromatosis-like neural tumors occurring in children, which allowed distinction from malignant peripheral nerve sheath tumors. 5 In this study we investigate the genetic abnormalities of a clinically aggressive infantile soft tissue tumor with unusual pathologic features, including strong and diffuse S100 protein expression for potential novel gene fusion discovery. Based on these histologic findings and immunprofile, the tumor was difficult to classify. The clinical presentation and morphologic appearance suggested the possibility of an infantile fibrosarcoma. However, the immunoprofile with strong S100 reactivity was not supportive and suggested instead a neuroectodermal line of differentiation, such as a cellular schwannoma or a malignant peripheral nerve sheath tumor.
| C AS E R E P O R T
Thus further molecular studies were undertaken which might hopefully provide insight into further sub-classification. RNA extracted from fresh frozen tissue was subjected to whole transcriptome paired-end RNA sequencing using Illumina platform, as previously described. 5 The data was then analyzed with FusionSeq computational method, which The follow-up available showed that 12 months after initial diagnosis, the child is alive with a stable residual tumor, no neurological sequelae and normal development under metronomic chemotherapy (vincristin, actinomycin D).
| DISCUSSION
We applied whole transcriptome sequencing in an unusual infantile MPNSTs show weak/focal reactivity for S100 protein and loss of H3K27me3 expression. 11, 12 Furthermore, infantile examples of high grade MPNST are exceedingly rare, and in our opinion most of them represent congenital cellular plexiform schwannomas. 7, 8 One additional tumor considered in the differential diagnosis was the recently described S100-positive lipofibromatosis-like neural tumor, which can occur in young children, including infants. 5 Similar to our case, these lesions may show areas of increased cellularity, scattered mitotic activity, and an infiltrative growth within adjacent adipose tissue. However, they also show CD34 and NTRK1 reactivity and NTRK1 gene rearrangements. Our case was negative for both NTRK1 overexpression and break-apart NTRK1 by FISH.
Interestingly, mesenchymal tumors with recurrent gene fusions often lack an established histogenesis or a characteristic immunoprofile, thus having an ambiguous line of differentiation. Particularly conflicting is the group of translocation-associated tumors with S100
protein expression in the absence of SOX10 reactivity. One example is ossifying fibromyxoid tumor, a translocation positive neoplasm of unknown line of differentiation, with consistent S100 protein reactivity. 13 Another example is the biphenotypic sinonasal sarcoma, a tumor with dual neural and muscle differentiation, harboring a PAX3-MAML3 gene fusion in most cases. 14 The so-called "neural phenotype" was defined on the basis of its S100 protein expression, in the absence of SOX10 staining. Lastly, the most recent example is the lipofibromatosis-like neural tumor with recurrent NTRK1-related fusions, in which the neural phenotype was defined based on its consistent S100 protein reactivity, but similarly lacking SOX10 positivity. domains to an intact MET kinase domain. More recently, MET fusions have been reported in a subset of pediatric glioblastomas, 16 with similar MET breakpoints as ours.
We describe herein a fast growing, locally aggressive infantile spindle cell sarcoma, with a partial neural phenotype defined by strong S100 protein reactivity. Whole transcriptome sequencing detected a TFG-MET gene fusion, which resulted in MET overexpression at both mRNA and protein levels. This is the first example of MET protooncogene activation through chromosomal translocation in a sarcoma patient and expands the pathologic spectrum of fusion-positive infantile sarcomas. It remains to be determined if a MET fusion-positive genotype translates to a favorable outcome, similar to other infantile/ congenital spindle cell sarcomas (i.e., fibrosarcoma, spindle cell rhabdomyosarcoma). Further studies are also needed to establish if the infantile sarcomas with MET related fusions represent a stand-alone pathologic entity or else may fit within the infantile fibrosarcoma spectrum despite strong S100 protein reactivity.
